Century Therapeutics, Inc. (IPSC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 60/100 (HIGH), 12.0 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 30.0% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
- Century Therapeutics Appoints Joseph Truitt to Board of Directors
- Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
- Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses
- Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
- Century Therapeutics Reports First Quarter Financial Results and Business Updates
- Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
- H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Century Therapeutics, Inc..
Full IPSC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.